Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer

Journal of Clinical Oncology

Volumn 20, Issue 8, 2002, Pages 1996-2004

  Ross, P ^a   Nicolson, M ^a   Cunningham, D ^a   Valle, J ^a   Seymour, M ^a   Harper, P ^a   Price, T ^a   Anderson, H ^a   Iveson, T ^a   Hickish, T ^a   Lofts, F ^a   Norman, A ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUOROURACIL; MITOMYCIN;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; ESOPHAGUS CARCINOMA; FEMALE; FEVER; HUMAN; INFECTION; LETHARGY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; STOMACH CARCINOMA; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; EPIRUBICIN; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MITOMYCINS; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0037090686     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.08.105     Document Type: Article

References (40)

1. Chemotherapy followed by operation alone in the treatment of patients with localized esophageal cancer: A preliminary report of intergroup study 113 (RTOG 89-11)
2. Randomised comparison of fluorouracil, epidoxirubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with nonresectable gastric cancer
3. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer
4. Cost effectiveness of palliative chemotherapy in advanced gastrointestinal cancer
5. Epirubicin, cisplatin and 5-fluorouracil (ECF) is highly effective in advanced gastric cancer
6. Gastric cancer: Chemotherapy of advanced disease
7. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high dose folinic acid
8. A phase II study of cisplatin in advanced gastric cancer
9. Epirubicin: A review of the pharmacology and adverse events of an adriamycin analogue
10. A phase III randomised study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer
11. Phase II study of doxorubicin versus epirubicin in advanced breast cancer
12. Randomised, comparative study of combination chemotherapy in advanced gastric cancer: 5-Fluorouracil and cisplatin (FP) versus 5-fluorouracil, cisplatin and 4′-epirubicin (FREPIR)
13. Epirubicin, cisplatin and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: Reponse, toxicity, quality of life, and survival
14. Epirubicin, cisplatin and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer: An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report
15. The use of a new combination chemotherapy: Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) in upper gastrointestinal (GI) tumors (Meeting abstract)
16. Significant palliation of advanced gastric/esophageal adenocarcinoma (g-o/c) with laser endoscopy and combination chemotherapy
17. Neoadjuvant chemotherapy in gastro-esophageal cancer using epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF)
18. A randomized trial comparing ECF with FAMTX in advanced esophagogastric cancer
19. The synergistic anti-neoplastic activity of combinations of mitomycins with either 6-thioguanine or 5-fluorouracil
20. Time-dependent interactions between 5-fluorouracil and mitomycin C on a human colon cancer cell line, HCT- 8 in vitro
21. A prospective randomized trial of protracted venous infusion (PVI) 5-FU with or without mitomycin C (MMC) in advanced colorectal cancer
22. A phase II study in advanced gastric cancer using epirubicin and cisplatin in combination with continuous 5-FU (ECF)
23. Reporting results of cancer treatment
24. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life instrument for use in the international clinical trials in oncology
25. Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses
26. Nonparametric estimation from incomplete observations
27. Asymptotically efficient invariant procedures
28. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomised trial
29. 5-Fluorouracil, adriamycin and mitomycin C (FAM) combination chemotherapy in the treatment of advanced gastric cancer
30. High-dose MTX/5FU and adriamycin for gastric cancer
31. An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer
32. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: A step ahead in the treatment of advanced gastric cancer - A trial of the European Organization for Research and Treatment of Cancer Gasttrointestinal Tract Cooperative Group
33. Phase II study with the combination of etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer
34. FAMTX versus etoposide, doxorubicin, and cisplatin: A randomized assignment trial in gastric cancer
35. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer